Ascendis Pharma Director Lars Holtug Files Form 144 for Tax-Related Share Sale
Ascendis Pharma A/S
Subscribe to track ASND
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Ascendis Pharma A/S ($ASND) – Form 144 Notice of Proposed Sale • Insider: Lars Holtug (Director) • Securities: Ordinary Shares • Shares to Sell: 236 (~$62.33K) • Approx. Date: 09/02/2026 • Broker: Citigroup Global Markets • Purpose: Sale of shares to cover income tax liabilities from compensation awards.
Comprehensive Analysis
Executive Summary
On September 2, 2026, Lars Holtug, a Director at Ascendis Pharma A/S ($ASND), filed a Form 144 notice covering the proposed sale of 236 Ordinary Shares with an aggregate market value of approximately $62,334.59 (indicative price of $264.13 per share). The sale is being executed via Citigroup Global Markets.
Transaction Details
- Security: Ordinary Shares
- Proposed Sale Units: 236
- Aggregate Market Value: $62,334.59
- Acquisition Source: Acquired via Share Plan Account as equity compensation on March 2, 2026.
- Transaction Purpose: Footnotes clarify this is a routine sale of shares to cover applicable income taxes.
Market & Governance Context
- Significance: Low.
- The volume of 236 shares is negligible relative to the issuer's 61,977,408 outstanding shares.
- Sell-to-cover transactions to satisfy tax obligations upon vesting or compensation distribution are standard corporate practices and do not represent a shift in insider sentiment regarding the company's fundamentals.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.